Exscientia Enrols First Patient in Phase 1/2 "ELUCIDATE" Trial Assessing GTAEXS617 in Advanced Solid Tumours
Portfolio Pulse from Benzinga Newsdesk
Exscientia plc (NASDAQ:EXAI) has enrolled the first patient in its Phase 1/2 'ELUCIDATE' study evaluating GTAEXS617, a CDK7 inhibitor, for the treatment of advanced solid tumours. The trial will assess the safety, efficacy and pharmacokinetics of '617 across multiple ascending doses in patients with various types of cancer. '617 was designed by Exscientia in collaboration with GT Apeiron.
July 10, 2023 | 11:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Exscientia's initiation of the Phase 1/2 trial for GTAEXS617 could potentially impact the company's stock positively if the trial results are promising.
The initiation of a clinical trial is a significant milestone for a biotech company like Exscientia. If the trial results are positive, it could lead to potential regulatory approval and commercialization of the drug, which would significantly boost the company's revenues and potentially its stock price.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100